Featured Research

from universities, journals, and other organizations

GOLFIG increased progression-free survival in colorectal cancer patients, study suggests

Date:
April 6, 2011
Source:
American Association for Cancer Research
Summary:
Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival, according to Phase III study results.

Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival, according to Phase III study results presented at the AACR 102nd Annual Meeting 2011, held in Orlando, Florida, April 2-6.

Related Articles


Patients with advanced colorectal cancer are typically treated with combination chemotherapy with fluorouracil or the derivative product, capecitabine with or without levofolinic acid with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) given alone, or with the monoclonal antibodies bevacizumab, cetuximab or panitumumab.

"These combinations have been successful in inducing tumor regression, retarding disease progression and increasing overall survival. However, the average progression-free survival and overall survival are still no more than eight to 10 months and 20 to 22 months, respectively," said Pierpaolo Correale, M.D., Ph.D., an oncologist at the Siena University School of Medicine in Italy.

This study was started in 2005, before monoclonal antibodies were routinely used. Correale and colleagues added gemcitabine to FOLFOX followed by granulocyte-macrophage colony stimulating factor and low-dose aldesleukine (GOLFIG) to boost the immune system in an effort to fight cancer.

The researchers randomized 130 patients to receive GOLFIG or FOLFOX for a maximum of 12 cycles and then receive maintenance treatment until disease progression. The study was designed to follow the patients in both arms until death, but was ended early due to significantly better results seen with the GOLFIG regimen.

So far, the patients who received GOLFIG had a progression-free survival of 16.5 months compared with the 7.5 months recorded in those patients who received FOLFOX.

"Based on our experience and results to date, we believe that the GOLFIG regimen is superior to FOLFOX chemotherapy in terms of efficacy and comparable in terms of toxicity and cost," said Correale. "We were very surprised to find such a significant difference in terms of overall survival with this low number of patients."

The challenge for the future will be to compare GOLFIG regimen with regimens containing monoclonal antibodies, he said.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "GOLFIG increased progression-free survival in colorectal cancer patients, study suggests." ScienceDaily. ScienceDaily, 6 April 2011. <www.sciencedaily.com/releases/2011/04/110406085045.htm>.
American Association for Cancer Research. (2011, April 6). GOLFIG increased progression-free survival in colorectal cancer patients, study suggests. ScienceDaily. Retrieved February 28, 2015 from www.sciencedaily.com/releases/2011/04/110406085045.htm
American Association for Cancer Research. "GOLFIG increased progression-free survival in colorectal cancer patients, study suggests." ScienceDaily. www.sciencedaily.com/releases/2011/04/110406085045.htm (accessed February 28, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, February 28, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could a $34 Smartphone Device Improve HIV Diagnosis in Africa?

Could a $34 Smartphone Device Improve HIV Diagnosis in Africa?

Reuters - Innovations Video Online (Feb. 27, 2015) A dongle that plugs into a Smartphone mimics a lab-based blood test for HIV and syphilis and can detect the diseases in 15 minutes, say researchers. Tara Cleary reports. Video provided by Reuters
Powered by NewsLook.com
Doctor Says Head Transplants Possible Within Two Years

Doctor Says Head Transplants Possible Within Two Years

Buzz60 (Feb. 27, 2015) An Italian doctor is saying he could stick someone&apos;s head onto someone else&apos;s body. Patrick Jones (@Patrick_E_Jones) reports. Video provided by Buzz60
Powered by NewsLook.com
How Your Dentist Could Help Screen You For Diabetes

How Your Dentist Could Help Screen You For Diabetes

Newsy (Feb. 27, 2015) A new study from researchers at New York University suggests dentists could soon use blood samples taken from patients&apos; mouths to test for diabetes. Video provided by Newsy
Powered by NewsLook.com
The Best Tips to Makeover Your Health

The Best Tips to Makeover Your Health

Buzz60 (Feb. 27, 2015) If you&apos;re looking to boost your health this season, there are a few quick and easy steps to prompt you for success. Krystin Goodwin (@Krystingoodwin) has the best tips to give your health a makeover this spring! Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins